Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis.
Identifieur interne : 000420 ( PubMed/Checkpoint ); précédent : 000419; suivant : 000421Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis.
Auteurs : R A Ngala ; K. FiankoSource :
- African health sciences [ 1729-0503 ] ; 2013.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Facteurs de risque, Femelle, Ghana (épidémiologie), Humains, Hyperglycémie (sang), Hyperglycémie (épidémiologie), Hyperglycémie (étiologie), Hyperlipidémies (sang), Hyperlipidémies (épidémiologie), Hyperlipidémies (étiologie), Infections à VIH (), Infections à VIH (sang), Infections à VIH (traitement médicamenteux), Infections à VIH (épidémiologie), Lipides (sang), Mâle, Numération des lymphocytes CD4, Prévalence, Thérapie antirétrovirale hautement active (effets indésirables), VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Études transversales.
- MESH :
- effets indésirables : Thérapie antirétrovirale hautement active.
- sang : Hyperglycémie, Hyperlipidémies, Infections à VIH, Lipides.
- traitement médicamenteux : Infections à VIH.
- épidémiologie : Ghana, Hyperglycémie, Hyperlipidémies, Infections à VIH.
- étiologie : Hyperglycémie, Hyperlipidémies.
- Adulte, Adulte d'âge moyen, Facteurs de risque, Femelle, Humains, Infections à VIH, Mâle, Numération des lymphocytes CD4, Prévalence, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Études transversales.
- Wicri :
- geographic : Ghana.
English descriptors
- KwdEn :
- Adult, Antiretroviral Therapy, Highly Active (adverse effects), CD4 Lymphocyte Count, Cross-Sectional Studies, Female, Ghana (epidemiology), HIV Infections (blood), HIV Infections (complications), HIV Infections (drug therapy), HIV Infections (epidemiology), HIV-1, Humans, Hyperglycemia (blood), Hyperglycemia (epidemiology), Hyperglycemia (etiology), Hyperlipidemias (blood), Hyperlipidemias (epidemiology), Hyperlipidemias (etiology), Lipids (blood), Male, Middle Aged, Prevalence, Risk Factors.
- MESH :
- chemical , blood : Lipids.
- geographic , epidemiology : Ghana.
- adverse effects : Antiretroviral Therapy, Highly Active.
- blood : HIV Infections, Hyperglycemia, Hyperlipidemias.
- complications : HIV Infections.
- drug therapy : HIV Infections.
- epidemiology : HIV Infections, Hyperglycemia, Hyperlipidemias.
- etiology : Hyperglycemia, Hyperlipidemias.
- Adult, CD4 Lymphocyte Count, Cross-Sectional Studies, Female, HIV-1, Humans, Male, Middle Aged, Prevalence, Risk Factors.
Abstract
Diet and genetic predisposition significantly affect lipid metabolism in the individual. This metabolic effect is further challenged in patients infected with HIV and on HAART. The prolonged use of HAART is associated with lipodystrophy, dyslipidemia, and insulin resistance.
DOI: 10.4314/ahs.v13i4.35
PubMed: 24940339
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:24940339Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis.</title><author><name sortKey="Ngala, R A" sort="Ngala, R A" uniqKey="Ngala R" first="R A" last="Ngala">R A Ngala</name><affiliation><nlm:affiliation>Department of Molecular Medicine, Kwame Nkrumah University of Science &Technology.</nlm:affiliation><wicri:noCountry code="subField">Kwame Nkrumah University of Science &Technology</wicri:noCountry></affiliation></author><author><name sortKey="Fianko, K" sort="Fianko, K" uniqKey="Fianko K" first="K" last="Fianko">K. Fianko</name><affiliation><nlm:affiliation>Department of Biochemistry, Ghana Health Service.</nlm:affiliation><wicri:noCountry code="subField">Ghana Health Service</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:24940339</idno><idno type="pmid">24940339</idno><idno type="doi">10.4314/ahs.v13i4.35</idno><idno type="wicri:Area/PubMed/Corpus">000301</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000301</idno><idno type="wicri:Area/PubMed/Curation">000301</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000301</idno><idno type="wicri:Area/PubMed/Checkpoint">000301</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000301</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis.</title><author><name sortKey="Ngala, R A" sort="Ngala, R A" uniqKey="Ngala R" first="R A" last="Ngala">R A Ngala</name><affiliation><nlm:affiliation>Department of Molecular Medicine, Kwame Nkrumah University of Science &Technology.</nlm:affiliation><wicri:noCountry code="subField">Kwame Nkrumah University of Science &Technology</wicri:noCountry></affiliation></author><author><name sortKey="Fianko, K" sort="Fianko, K" uniqKey="Fianko K" first="K" last="Fianko">K. Fianko</name><affiliation><nlm:affiliation>Department of Biochemistry, Ghana Health Service.</nlm:affiliation><wicri:noCountry code="subField">Ghana Health Service</wicri:noCountry></affiliation></author></analytic><series><title level="j">African health sciences</title><idno type="eISSN">1729-0503</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antiretroviral Therapy, Highly Active (adverse effects)</term><term>CD4 Lymphocyte Count</term><term>Cross-Sectional Studies</term><term>Female</term><term>Ghana (epidemiology)</term><term>HIV Infections (blood)</term><term>HIV Infections (complications)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (epidemiology)</term><term>HIV-1</term><term>Humans</term><term>Hyperglycemia (blood)</term><term>Hyperglycemia (epidemiology)</term><term>Hyperglycemia (etiology)</term><term>Hyperlipidemias (blood)</term><term>Hyperlipidemias (epidemiology)</term><term>Hyperlipidemias (etiology)</term><term>Lipids (blood)</term><term>Male</term><term>Middle Aged</term><term>Prevalence</term><term>Risk Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Facteurs de risque</term><term>Femelle</term><term>Ghana (épidémiologie)</term><term>Humains</term><term>Hyperglycémie (sang)</term><term>Hyperglycémie (épidémiologie)</term><term>Hyperglycémie (étiologie)</term><term>Hyperlipidémies (sang)</term><term>Hyperlipidémies (épidémiologie)</term><term>Hyperlipidémies (étiologie)</term><term>Infections à VIH ()</term><term>Infections à VIH (sang)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (épidémiologie)</term><term>Lipides (sang)</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>Prévalence</term><term>Thérapie antirétrovirale hautement active (effets indésirables)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Études transversales</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Lipids</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Ghana</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antiretroviral Therapy, Highly Active</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>HIV Infections</term><term>Hyperglycemia</term><term>Hyperlipidemias</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Thérapie antirétrovirale hautement active</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>HIV Infections</term><term>Hyperglycemia</term><term>Hyperlipidemias</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Hyperglycemia</term><term>Hyperlipidemias</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Hyperglycémie</term><term>Hyperlipidémies</term><term>Infections à VIH</term><term>Lipides</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Ghana</term><term>Hyperglycémie</term><term>Hyperlipidémies</term><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Hyperglycémie</term><term>Hyperlipidémies</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>CD4 Lymphocyte Count</term><term>Cross-Sectional Studies</term><term>Female</term><term>HIV-1</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prevalence</term><term>Risk Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Infections à VIH</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>Prévalence</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Études transversales</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Diet and genetic predisposition significantly affect lipid metabolism in the individual. This metabolic effect is further challenged in patients infected with HIV and on HAART. The prolonged use of HAART is associated with lipodystrophy, dyslipidemia, and insulin resistance.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24940339</PMID><DateCreated><Year>2014</Year><Month>06</Month><Day>18</Day></DateCreated><DateCompleted><Year>2015</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1729-0503</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>African health sciences</Title><ISOAbbreviation>Afr Health Sci</ISOAbbreviation></Journal><ArticleTitle>Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis.</ArticleTitle><Pagination><MedlinePgn>1107-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4314/ahs.v13i4.35</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Diet and genetic predisposition significantly affect lipid metabolism in the individual. This metabolic effect is further challenged in patients infected with HIV and on HAART. The prolonged use of HAART is associated with lipodystrophy, dyslipidemia, and insulin resistance.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the prevalence of lipid dysregulation and dysglycaemia in HIV infected patients on HAART in the Kumasi metropolis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This cross sectional study was conducted between October 2009 and June 2010, and 305 HIV-infected patients consisting of 164 patients on HAART for at least six months and 141 HAART-naive patients constituted HIV-positive patients, not on HAART and whose CD4 were not below 320 cell/ml as the control. Data was analyzed using Graph Pad Prism (version 5.0). Unpaired t-test, linear and multivariate regression analyses, was used to predict glucose level from the various parameters. Anthropometric parameters consisting of body weight, waist and hip circumferences, height, bicep and triceps skin fold were measured with a pair of calipers. Lipid profile and fasting blood glucose were determined by enzymatic methods. CD4 counts and hemoglobin were determined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fasting plasma, glucose (3.81±0.08mmol/l, 4.48±0.17mmol/l), total cholesterol (3.05± 0.0 8mmol/l, 4.54±0.08mmol/l) LDL (2.24±0.07mmol/l, 2.87±0.07mmol/l) and HDL (0.85±0.04mmol/l, 0.97±0.03mmol/l) between the control and case respectively were significantly raised (P< 0.001), though within the physiological range. The significantly increased hip and waist circumferences, waist-to-hip ratio (0.85±0.22, 0.88±0.01) of the control and case correlated with lipodystrophy.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">HAART was associated with lipodystrohy and, the risk of developing type II diabetes among the HAART experienced group was 5 times higher than the HAART naive group.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ngala</LastName><ForeName>R A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Kwame Nkrumah University of Science &Technology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fianko</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Ghana Health Service.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Uganda</Country><MedlineTA>Afr Health Sci</MedlineTA><NlmUniqueID>101149451</NlmUniqueID><ISSNLinking>1680-6905</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2001 Jan 26;15(2):231-9</RefSource><PMID Version="1">11216932</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1998 May 7;12(7):F51-8</RefSource><PMID Version="1">9619798</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 1994 Sep;17(9):961-9</RefSource><PMID Version="1">7988316</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1999 Sep 10;13(13):1659-67</RefSource><PMID Version="1">10509567</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Chem Lab Med. 2007;45(7):815-21</RefSource><PMID Version="1">17617020</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Swiss Med Wkly. 2009 Oct 3;139(39-40):564-70</RefSource><PMID Version="1">19838874</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2006 Mar;185(1):1-11</RefSource><PMID Version="1">16297390</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nurse Pract. 2010 Jul;35(7):32-7; quiz 37-8</RefSource><PMID Version="1">20555242</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2005;10(5):663-70</RefSource><PMID Version="1">16152760</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2002 Mar 29;16(5):F1-8</RefSource><PMID Version="1">11964551</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 2011 Apr;96(4):885-93</RefSource><PMID Version="1">21474685</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1990 Aug 16;323(7):439-45</RefSource><PMID Version="1">2374566</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1666-73</RefSource><PMID Version="1">17284576</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Obes Relat Metab Disord. 1992 Mar;16(3):177-84</RefSource><PMID Version="1">1317826</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Public Health. 2009 May;123(5):365-70</RefSource><PMID Version="1">19362725</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocrinology. 1995 May;136(5):2143-9</RefSource><PMID Version="1">7720663</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):443-8</RefSource><PMID Version="1">11391163</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes. 1985 Oct;34(10):1055-8</RefSource><PMID Version="1">4043554</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Diabetol. 2003 Oct;40 Suppl 1:S130-3</RefSource><PMID Version="1">14618452</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2005 Jan;178(1):165-72</RefSource><PMID Version="1">15585214</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Endocrinol Metab. 2003 Feb;284(2):E274-80</RefSource><PMID Version="1">12388139</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Gen Intern Med. 2002 Oct;17(10):797-810</RefSource><PMID Version="1">12390557</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Rev Prat. 2006 May 15;56(9):987-94</RefSource><PMID Version="1">16775979</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1998 Mar 21;351(9106):867-70</RefSource><PMID Version="1">9525364</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):199-202</RefSource><PMID Version="1">15905737</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1998 Apr 16;12(6):F37-9</RefSource><PMID Version="1">9583592</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1999 Jun 19;353(9170):2093-9</RefSource><PMID Version="1">10382692</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2010 Jan 15;201(2):285-92</RefSource><PMID Version="1">19954384</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb. 1991 May-Jun;11(3):495-500</RefSource><PMID Version="1">2029492</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2007 Jan;30(1):113-9</RefSource><PMID Version="1">17192343</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2002 Feb 1;29(2):117-21</RefSource><PMID Version="1">11832679</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Med Genet. 2011;12:120</RefSource><PMID Version="1">21939545</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cardiol Rev. 2009 Sep-Oct;17(5):211-5</RefSource><PMID Version="1">19690471</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2004 Jan;53(1):10-4</RefSource><PMID Version="1">14645323</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr HIV Res. 2006 Jan;4(1):79-85</RefSource><PMID Version="1">16454713</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 1998 Jul;27(1):68-72</RefSource><PMID Version="1">9675454</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Endocrinol Metab. 2004 Feb;286(2):E261-71</RefSource><PMID Version="1">14532165</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Chem. 1988 Jan;34(1):193-201</RefSource><PMID Version="1">3338168</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Croat Med J. 2003 Oct;44(5):576-8</RefSource><PMID Version="1">14515416</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2003 Sep 1;37(5):613-27</RefSource><PMID Version="1">12942391</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J HIV Ther. 2004 May;9(2):34-40</RefSource><PMID Version="1">15238874</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Open AIDS J. 2009 Jul 16;3:31-7</RefSource><PMID Version="1">19639034</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023241" MajorTopicYN="N">Antiretroviral Therapy, Highly Active</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006943" MajorTopicYN="N">Hyperglycemia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006949" MajorTopicYN="N">Hyperlipidemias</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4056472</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HAART</Keyword><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">Hypertriglyceridemia</Keyword><Keyword MajorTopicYN="N">non-nucleoside reverse transcriptase inhibitor</Keyword><Keyword MajorTopicYN="N">nucleoside reverse transcriptase inhibitor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24940339</ArticleId><ArticleId IdType="doi">10.4314/ahs.v13i4.35</ArticleId><ArticleId IdType="pii">jAFHS.v13.i4.pg1107</ArticleId><ArticleId IdType="pmc">PMC4056472</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Fianko, K" sort="Fianko, K" uniqKey="Fianko K" first="K" last="Fianko">K. Fianko</name><name sortKey="Ngala, R A" sort="Ngala, R A" uniqKey="Ngala R" first="R A" last="Ngala">R A Ngala</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000420 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000420 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:24940339
|texte= Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:24940339" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |